Codexis, Inc. (NASDAQ:CDXS – Get Free Report)’s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.95 and traded as high as $4.30. Codexis shares last traded at $4.16, with a volume of 487,277 shares changing hands.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on CDXS shares. Benchmark reissued a “hold” rating on shares of Codexis in a research report on Monday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $11.00 target price on shares of Codexis in a research report on Friday, November 22nd.
Read Our Latest Report on Codexis
Codexis Stock Performance
Institutional Investors Weigh In On Codexis
Several institutional investors and hedge funds have recently made changes to their positions in CDXS. Private Advisor Group LLC increased its position in shares of Codexis by 1.3% during the third quarter. Private Advisor Group LLC now owns 278,699 shares of the biotechnology company’s stock valued at $858,000 after acquiring an additional 3,458 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Codexis by 23.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,103,442 shares of the biotechnology company’s stock worth $3,399,000 after purchasing an additional 209,207 shares during the period. abrdn plc grew its position in Codexis by 62.5% in the 3rd quarter. abrdn plc now owns 800,410 shares of the biotechnology company’s stock worth $2,465,000 after purchasing an additional 307,762 shares during the period. Perkins Capital Management Inc. grew its position in Codexis by 2.8% in the 3rd quarter. Perkins Capital Management Inc. now owns 164,100 shares of the biotechnology company’s stock worth $505,000 after purchasing an additional 4,500 shares during the period. Finally, GSA Capital Partners LLP grew its position in shares of Codexis by 83.5% during the 3rd quarter. GSA Capital Partners LLP now owns 99,629 shares of the biotechnology company’s stock valued at $307,000 after acquiring an additional 45,337 shares during the period. Institutional investors own 78.54% of the company’s stock.
Codexis Company Profile
Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.
Featured Stories
- Five stocks we like better than Codexis
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 2 Stocks Riding the Dominance of America’s Natural Gas Exports
- How to Capture the Benefits of Dividend Increases
- Buffett’s on the Sidelines – Should You Follow?
- What is the Nasdaq? Complete Overview with History
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.